PRINTO (the Paediatric Rheumatology International Trials Organisation)

This study is currently recruiting participants.

Verified by Institute of Child Health, December 2006

Sponsored by:	Institute of Child Health
Information provided by:	Institute of Child Health
ClinicalTrials.gov Identifier:	NCT00415935

Purpose

A comparison of outcome in children with JIA who are in remission on MTX, when MTX is then stopped for either 6 or 12 months

Condition	Intervention
Juvenile Idiopathic Arthritis	Drug: methotrexate

MedlinePlus related topics: Juvenile Rheumatoid Arthritis

Drug Information available for: Methotrexate

U.S. FDA Resources

Study Type:	Observational
Study Design:	Longitudinal, Defined Population, Prospective Study

Further study details as provided by Institute of Child Health:

Estimated Study Completion Date:

December 2006

Eligibility

Ages Eligible for Study:	up to 16 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Any child with JIA who has gone into remission using methotrexate

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00415935

Contacts

Contact: Lucy Wedderburn, Dr

l.wedderburn@ich.ucl.ac.uk

Locations

United Kingdom
Rheumatology ICH	Recruiting
London, United Kingdom, WC1N 1EH
Contact: Lucy Wedderburn, Dr l.wedderburn@ich.ucl.ac.uk

Sponsors and Collaborators

Institute of Child Health

Investigators

Principal Investigator:

Lucy Wedderburn, Dr

Institute Of Child Health and Great Ormond Street Hospital

More Information

Study ID Numbers:	04RU01
Study First Received:	December 22, 2006
Last Updated:	December 23, 2006
ClinicalTrials.gov Identifier:	NCT00415935
Health Authority:	United Kingdom: Research Ethics Committee

Study placed in the following topic categories:

Folic Acid
Autoimmune Diseases
Arthritis, Juvenile Rheumatoid
Musculoskeletal Diseases
Joint Diseases

Arthritis
Connective Tissue Diseases
Arthritis, Rheumatoid
Methotrexate
Rheumatic Diseases

Additional relevant MeSH terms:

Antimetabolites
Antimetabolites, Antineoplastic
Immunologic Factors
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Reproductive Control Agents

Folic Acid Antagonists
Abortifacient Agents, Nonsteroidal
Immunosuppressive Agents
Pharmacologic Actions
Therapeutic Uses
Abortifacient Agents
Antirheumatic Agents
Dermatologic Agents
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on January 16, 2009